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PNPO deficiency is responsible of severe neonatal encephalopathy,
responsive to pyridoxal-5′-phosphate (PLP) or pyridoxine. Recent
studies widened the phenotype of this condition and detected new
genetic variants on PNPO gene, whose pathogenetic role and
clinical expression remain to be established. One of these muta-
tions, Arg116Gln, is of particular interest because of its later
onset of symptoms (beyond the first months of life) and its
peculiar epileptic manifestations in patients. This protein variant
was expressed as recombinant protein in E coli, purified to
homogeneity, and characterized with respect to structural andis an open access article under the CC BY license
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M.L. di Salvo et al. / Data in Brief 15 (2017) 868–875 869kinetic properties, stability, binding constants of cofactor flavin
mononucleotide (FMN) and product (PLP) in order to define the
molecular and structural bases of its pathogenicity.
For interpretation and discussion of reported data, together
with the description of clinical studies, refer to the article [1] (doi:
10.1016/j.ymgme.2017.08.003).
& 2017 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Protein biochemistry
ore specific subject area Biochemical characterization of enzyme mutant forms
ype of data Text file, Graph, Figures
ow data was acquired Data were acquired upon protein purification and spectrophotometric
measurements. Instruments used in this work were: Spectrophotometer
HP 8453 diode array, Spectropolarimeter Jasco 725, Spectrofluorimeter
Horiba Jobin-Ivon FluoroMax-3, FPLC AKTA PrimePlus GE Healthcareata format Raw, Analyzed
xperimental factors Wild type and mutant PNPO proteins, purified to homogeneity prior to
biochemical characterization
xperimental features Catalytic constants, melting temperature, and affinity for ligands for wild
type and mutant PNPO proteins were compared
ata source location Rome, Italy
ata accessibility Data are available with this articleDValue of the data
 The data describe the new purification protocol for recombinant human PNPO mutant forms.
 The data present structural and functional characterization of PNPO mutant forms.
 The data allow the determination of delivery capability of PLP from PNPO to PLP-dependent
enzymes.1. Data
The data presented in this paper refer to structural and functional characterization of a new
pathogenic PNPO mutant form, related to the onset of a peculiar epileptic status in patients. Fig. 1
shows insights into the active site structure of modeled human PNPO (Arg116Gln mutant form).
Figs. 2–5 show the characterization of Arg116Gln PNPO mutant.2. Experimental design, materials and methods
2.1. Molecular modeling
The three-dimensional structure of human PNPO (PDB Code: 1NRG) [2] was used as a starting
point to model the Arg116Gln mutant (Fig. 1). The mutation on protein structure was carried out using
the “Mutate model” script [3]. Procheck [4] was used to monitor the stereochemical quality of the
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Fig. 1. Upper panel: Structural comparison of wild type and mutant Arg116Gln form of PNPO (subunits within the dimer are
shown in green and cyan). The mutation is indicated in white sticks. Distances between the atoms involved in an ion-pair
interaction are also indicated, in Å. Lower panel: Close-up of the three-dimensional structure of the active site of human PNPO
(PDB 1NRG; [2]. The two protein subunits are shown in cyan end blue. Secondary structures are shown as cartoon, while Arg116
and Glu143 residues are depicted as sticks. FMN and PLP in the active site (A) are shown as sticks, in orange and yellow color,
respectively. Location of PLP in the secondary tight binding site (B)(shown as two different conformers) results from the
superimposition with E. coli PNPO three-dimensional structure in the complex with PLP (PDB 1G79; [12]).
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Fig. 2. UV–Vis absorption spectrum of purified human PNPO Arg116Gln mutant form. The enzyme exhibits absorption maxima
at 278 nm, 387 nm, and 450 nm typical of FMN-binding proteins.
Fig. 3. Dependence of initial velocity (vi) of PLP formation on PNP concentration. Wild type (closed circles, ), Arg116Gln PNPO
(open squares, ◊). All experimental points are the average7standard deviation of at least three independent measurements.
The continuous lines through the experimental points were obtained by non-least square fitting of experimental data to
Michaelis-Menten equation.
M.L. di Salvo et al. / Data in Brief 15 (2017) 868–875 871model, ProsaII [5] to measure the overall protein quality. Prediction of protein stability was carried out
using DUET server [6].
2.2. Expression and purification
PNPO forms were purified following a simplified procedure derived form a previous protocol [2].
Briefly, supernatant from cell lysis was directly loaded onto a HisTrap FPLC column and eluted with
imidazole (0–250 mM) in 50 mM Tris–HCl pH 7.6, 300 mM NaCl. Spectrum of Arg116Gln mutant is
shown in Fig. 2. Apo-enzyme was prepared as previously described [2].
2.3. Kinetic studies
Enzymatic assays were performed as previously described [7]. Experimental determinations are
depicted in Fig. 3. Km and kcat values are shown in Table 1 of Ref [1]. For enzyme stability experiments,
PNPO forms were left at either 37 or 42 °C at a final enzyme concentration of 0.3 μM. Enzymatic
assays were then performed with a final PNP concentration of 100 μM (See Figure 4 in Ref [1]).
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Fig. 4. A) Superdex 200 10/300 FPLC size exclusion chromatography. Elution profile of wild type (black line) and Arg116Gln
(red line) PNPO. Chromatographic separations were repeated using different protein batches, obtaining similar results; B) Far-
UV CD spectra of wild type (black lines) and Arg116Gln (red lines) at 20 °C and 40 °C (continuous and dashed line, respectively).
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One-hundred microliter samples of 10 μM Arg116Gln or 16 μMwild type PNPO were loaded onto a
Superdex 200 FPLC column and eluted using 50 mM sodium Hepes, pH 7.6, 150 mM NaCl (Fig. 4A).2.5. Circular dichroism measurements
Far-UV CD measurements were carried out at 20 and 40 °C in 50 mM sodium Hepes buffer pH 7.6,
150 mM NaCl with a protein concentration of 4 μM. The relative spectra are shown in Fig. 4B.2.6. PLP binding equilibrium
Analyses took advantage of protein intrinsic fluorescence quenching observed upon PLP binding as
previously described [8]. PLP binding curves are shown in Fig. 5. Data were fitted to Eq. (1), in which Frel
is the measured relative fluorescence at 348 nm, F0 is fluorescence in the absence of PLP, Finf is fluor-
escence at infinite PLP concentration, [PLP] is the total PLP concentration, [PNPO] stands for the total
protein concentration, and Kd is the dissociation constant of the equilibrium PLPþPNPO⇌PNPOPLP , where
0 1 2 3 4 5
1000000
1050000
1100000
1150000
1200000
1250000
PLPM
F 3
48
R116Q
Wild type
Fig. 5. Fluorescence emission quenching of PNPO (excitation wavelength of 280 nm, emission 348 nm) upon binding to PLP:
wild type (closed circles, ), Arg116Gln (open squares, ◊). The continuous (wild type) and dashed (Arg116Gln mutant) lines
through the experimental points were obtained by non-least square fitting of experimental data to Eq. (1).
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Frel ¼ F0− F0−Finf
 
PLP½ þ PNPO½ þKd−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
PLP½ þ PNPO½ þKdð Þ2−4 PNPO½ ½PLP
p
2
½PNPO ð1Þ
The fraction in Eq. (1) corresponds to the fraction of enzyme-bound PLP at equilibrium ½PNPOPLP eq½PNPO
 
.
PNPOPLP½ eq was derived from the equation for the dissociation constant of the binding equilibrium,
Kd ¼
PNPO½ − PNPOPLP½ ð Þ  PLP½ −½PNPOPLP ð Þ
½PNPOPLP 
as one of the two solutions of the quadratic equation
PNPOPLP½ 2− Kdþ PLP½ þ PNPO½ ð Þ  PNPOPLP½ þ PNPO½ ñ PLP½  ¼ 0
2.7. FMN binding
Dissociation constant for FMN binding to PNPO forms were analyzed by FMN fluorescence
quenching observed upon binding of the cofactor to apo-PNPO [9]. The saturation curves are shown in
Figure 3A of Ref [1]. The relative Kd values are reported in Table 1 of Ref [1]. Data were analyzed
according to Eq. (2), in which Frel is the measured relative fluorescence at 525 nm, F0 is fluorescence in
the absence of apo-PNPO, Finf is fluorescence at infinite apo-PNPO concentration, [APO] is the total
apo-enzyme concentration, [FMN] stands for the total cofactor concentration and Kd is the dissocia-
tion constant of the equilibrium APOþFMN⇌HOLO
Frel ¼ F0− F0−Finf
 
APO½ þ FMN½ þKd−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
APO½ þ FMN½ þKdð Þ2−4 FMN½ ½APO
p
2
½FMN ð2Þ
The fraction in Eq. (2) corresponds to the fraction of enzyme-bound FMN at equilibrium ½HOLOeq½FMN
 
.
HOLOeq
 
was derived from the equation for the dissociation constant of the binding equilibrium,
Kd ¼
FMN½ − HOLOeq
   APO½ −½HOLOeq 
½HOLOeq
as one of the two solutions of the quadratic equation
HOLOeq
 2− Kdþ APO½ þ FMN½ ð Þ  HOLOeq þ FMN½   APO½  ¼ 0
M.L. di Salvo et al. / Data in Brief 15 (2017) 868–8758742.8. Thermal denaturation
Protein samples (4 μM), were heated from 20 to 90 °C monitoring the dichroic activity at 220 nm
[10]. Denaturation curves were fitted to Eq. (3), in which θ220 is the measured ellipticity at 220 nm, Δθ
is the maximum ellipticity change, T is the temperature expressed in Celsius, Tm is the apparent
melting temperature, and n is the steepness of the sigmoid curve [10]:
θ220 ¼ Δθ
Tn
TnmþTn
	 

þconst ð3Þ
Denaturation curves are shown in Figure 3B of Ref [1].
2.9. Stoichiometry of PNPOPLP complexes
Wild type or Arg116Gln PNPO (150 μM) were mixed with 450 μM PLP and incubated at 30 °C for
one hour. Samples were run on P-6DG Bio-Gel. Fractions were analyzed by absorption spectra to
detect the presence of protein and PLP. Protein concentration was measured by Bradford assay. PLP
concentration was measured as in [11].
2.10. Transfer of tightly bound PLP
Protein samples saturated with PLP (PNPOPLP complexes) were mixed at a final concentration of
2 µM with equimolar amount of apo-human cytosolic serine hydroxymethyltransferase (hcSHMT). At
various time intervals, transfer of PLP was determined by measuring hcSHMT catalytic activity [11].
PLP transfer kinetics are shown in Figure 5 of Ref [1].Acknowledgements
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